

ICDs at End-of-Life: Do Term Limits Apply?

Craig S. Cameron, MD, FACC, FHRS Electrophysiologist – Oklahoma Heart Institute Lab Director – Hillcrest Hospital South

Oklahoma Heart





HEART RHYTHM SYMPOSIUM

Campaign Contributors and Lobbyists: (My Disclosures)

- Speaker Honoraria:
 - Biosense Webster
 - Daiichi Sankyo
 - Spectranetics
 - Zoll

- Research Involvement:
 - Medtronic
 - St. Jude Medical



HEART RHYTHM SYMPOSIUM



Case

THEN:

79 yo woman undergoes CRT-D implantation in May of 2011 for NICM (LVEF 30%), CHF – NYHA III, and LBBB (150 ms)

NOW:

84 yo woman with CRT-D at recommended replacement time with normal, chronic lead function.

- LVEF 55-60%
- NYHA II
- No history of appropriate therapies for VT/VF



HEART RHYTHM SYMPOSIUM

What now?

What should we do for her?

What options do we have?

Has she benefited from her CRT-D?



The Two Basic ICD Indications

Secondary Prevention:

 cardiac arrest survivors, patients with sustained VT or VF

Primary Prevention:

- patients at risk for sudden death, but who have not had a documented arrest or sustained VT/VF
 - Examples: ICM, NICM, HCM, inherited channelopathies, etc.




* 201> *

HEART RHYTHM SYMPOSIUM

Primary Prevention Trials

Trial (Follow-Up) Year Published	Number of Subjects	Study Group/Entry Criteria		Cause rtality ARR	
MADIT (2-yr analysis) 1996	196	Prior MI, EF ≤ 35%, NS VT, inducible VT, failed IV PA	59%	19%	
MADIT-II (2-yr analysis) 2002	1232	Prior MI (>1 month), EF <u><</u> 30%	28%	6%	
DEFINITE (2.5-yr analysis) 2004	458	Nonischemic CM, history of HF, EF \leq 35%, 10 PVCs/h or NSVT	44%	6%	
SCD-HeFT (5-yr analysis) 2005	2521	NYHA functional class II–III CHF, $EF \le 35\%$	23%	7%	HEART RHYTHM SYMPOSIUM




CLASS III


1. ICD therapy is not indicated for patients who do not have a reasonable expectation of survival with an acceptable functional status for at least 1 year, even if they meet ICD implantation criteria specified in the Class I, IIa, and IIb recommendations above. (*Level of Evidence: C*)



JACC Vol. 61, No. 3, 2013 January 22, 2013:e6-75

Continuous Dialogue and Education








HEART RHYTHM SYMPOSIUM

US Population Distribution by Age





HEART RHYTHM SYMPOSIUM

htttp://www.calculatedriskblog.com

US Population Distribution by Age



Comorbidities

- Heart Failure
- Coronary artery disease
- Valvular heart disease
- Diabetes
- Renal dysfunction
- Lung disease
- Cancer
- Cognitive dysfunction

- Depression
- Chronic pain
- Peripheral vascular disease
- Hepatic failure
- Arthritis/orthopedic diseases
- Strokes
- Hypertension
- Psychiatric limitations



HEART RHYTHM SYMPOSIUM

2012 ACCF/AHA/HRS Focused Update of the **2008 Guidelines for Device-Based Therapy** of Cardiac Rhythm Abnormalities

A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines

Careful selection based upon:


- Estimated life expectancy
- Consideration of comorbidities
- Procedural risk
- Patient preferences



HEART RHYTHM SYMPOSIUM

C. Tracy et Al. ACC/AHA/HRS Guidelines, JACC 2012


The National ICD Registry Report: Years 2010-



Initial Implants in the Elderly




Secondary Prevention in the Elderly: Pooled Data from AVID, CASH, CIDS



Use of implantable cardioverter-defibrillators for primary prevention in older patients: A systematic literature review and meta-analysis


All-Cause Mortality in Patient > 75 Years (11.7% of Pts)



Primary prevention ICDs may be beneficial in older patients

Kong M et al. Cardiol J 2011; 18, 5: 503–514

5399 ICD recipients in Ontario, Canada (Feb. 2007 to Sept. 2010) 3939 for primary prevention including 275 pts over 80 years (7%)



Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention

From the NCDR ICD Registry


- 12,420 Medicare beneficiaries undergoing first-time secondary prevention ICD implantation between 2006 and 2009
- mean age 75 years at the time of implantation
 - 25.3% <70 years of age
 - 25.7% were >80 years of age
- Examined 2 year risk of mortality, hospitalization, HF hospitalization, and SNF admission




HEART RHYTHM SYMPOSIUM


Betz, J.K. et al. J Am Coll Cardiol. 2017;69(3):265-74













D. Cumulative Incidence of Admission to a SNF B. Cumulative Incidence of All-Cause Hospitalization




Applicability of a Risk Score for Prediction of the Long-Term (8-Year) Benefit of the Implantable Cardioverter-Defibrillator

5 Risk factors:
1. NYHA > II
2. Age >70 years
3. BUN >26 mg/dl
4. QRS duration >0.12 s

5. Atrial fibrillation





Generator Replacement






HEART RHYTHM SYMPOSIUM

Appropriateness of Primary Prevention Implantable Cardioverter-Defibrillators at the Time of Generator Replacement Are Indications Still Met?



Retrospective chart review of 231 VA patients undergoing replacement of primary prevention ICD



Left Ventricular Function Does Not Predict the Risk of Death and Ventricular Tachyarrhythmias in Patients following Elective Implantable Cardioverter Defibrillator Generator Replacement

Single Center Retrospective Review of 175 Patients

	LVEF < 35 n=117	LVEF > 35 n=57	P value
Death	35 (30%)	14 (25%)	0.461
VTA	15 (13%)	5 (8%)	0.411

Median follow-up of 2.19 ± 2.23 years

Mohan, R. et al. Heart Rhythm Society Scientific Session 2015

Left Ventricular Function Does Not Predict the Risk of Death and Ventricular Tachyarrhythmias in Patients following Elective Implantable Cardioverter Defibrillator Generator Replacement

Single Center Retrospective Review of 175 Patients

Predictors of All-Cause Mortality:

	HR	95% CI	Р
Time dependent VTA post generator replacement ¹	2.25	1.06-4.62	0.032
Age at GR ²	1.06	1.02-1.09	0.002

Mohan, R. et al. Heart Rhythm Society Scientific Session 2015

Left Ventricular Function Does Not Predict the Risk of Death and Ventricular Tachyarrhythmias in Patients following Elective Implantable Cardioverter Defibrillator Generator Replacement


Single Center Retrospective Review of 175 Patients

Predictors of VTA after generator replacement:

	HR	95% CI	р
NYHA class III-IV	4.11	1.49-11.42	0.006
VTA prior to GR	2.57	0.99-6.62	0.051

Mohan, R. et al. Heart Rhythm Society Scientific Session 2015

Arrhythmic Risk Following Recovery of Left Ventricular Ejection Fraction in Patients with Primary Prevention ICD Single Center Retrospective Analysis of 286 Patients



Arrhythmic Risk Following Recovery of Left Ventricular Ejection Fraction in Patients with Primary Prevention ICD Single Center Retrospective Analysis of 286 Patients

	ISCHEMIC CARDIOMYOPATHY		NON-ISCHEMIC CARDIOMYOPATHY
Α	SUBGROUP	В	SUBGROUP

"In conclusion, patients with nonischemic cardiomyopathy who improved their LVEF to >35% after primary prevention ICD implantation were at very low absolute arrhythmic risk. Our study raises the possibility that the LVEF cutoff to safely withhold ICD replacement might be higher in patients with ischemic compared to nonischemic cardiomyopathy."

Follow-up time (years) PACE 2016; 39:680–689

IVEE Bocovory

"It's JUST a gen change, right?"






HEART RHYTHM SYMPOSIUM

Complication Rates Associated With Pacemaker or Implantable Cardioverter-Defibrillator Generator Replacements and Upgrade Procedures

Results From the REPLACE Registry



Circulation. 2010;122:1553-1561

Table 1	Characteristics of Patients at Initial ICD Implantation and at the Time of ICD Replacement			
(stage	III or greater)			
Hyperter	ision	170 (74)	189 (82)	<0.01
Diabetes	;	99 (43)	107 (46)	<0.01
Atrial fib	rillation	37 (16)	56 (24)	<0.01
History o	f stroke	33 (14)	37 (16)	0.13
Dialysis	dependent	1 (<1)	2 (1)	0.50
Neoplast	ic disease	6 (3)	33 (14)	<0.01
Cognitive	e impairment	5 (2)	9 (4)	0.13
Nursing	facility resident	1 (<1)	2 (1)	0.50
Medication	use			
ACE inhi	bitor or ARB	198 (86)	194 (84)	0.39
Beta-blo	cker	177 (77)	200 (87)	<0.01
Antiarrhy	thmic drug	29 (13)	37 (16)	0.10

Many comorbidities appear after ICD implantation.




HEART RHYTHM SYMPOSIUM


J Am Coll Cardiol 2014;63:2388-94

REPLACE DARE (Death After Replacement Evaluation) Score


Determinants of All-Cause Mortality After Implantable Device Replacement or Upgrade From the REPLACE Registry




- 1=Yes]
- NYHA Class [0=0, I, II; 1=III, IV]
- CKD stage [1–5]
- Class I or III antiarrhythmic drug use [0=No; 1=Yes]
- History of cerebrovascular disease [0=No; 1=Yes]
- Age quartiles [1=<63; 2=63-72; 3=73-79; 4=80+]



Back to Our Case...



Upcoming Political Scandal: The DF-4 Dilemma



End-of-Life Discussions





HEART RHYTHM SYMPOSIUM



"When I die, I want to die like my grandfather who died peacefully in his sleep. Not screaming like all the passengers in his car." - Will Rogers



Case #2 (From March, 2016)

73 yo man with CAD – s/p inferior MI, ICM, CHF, VT – s/p RFA, h/o AF, upgraded from dual chamber ICD to CRT-d 4/14 for complete AV block

- Stable NYHA III CHF sx.
- No ICD shocks since prio to VT ablation
- Last ATP for slow VT 12/15 (single episode)
- Progressive Alzheimer's dementia, impacting QOL to the point that patient no longer wishes to receive ATP or ICD shock



* 2012 *

HEART RHYTHM SYMPOSIUM

When should we de-activate a patient's ICD?



The short answer to the question: Whenever the patient or his/her surrogate ask us to.



HEART RHYTHM SYMPOSIUM

Our Ethical & Legal Responsibilities

Fundamental underlying principle of both Ethical and Legal aspects of ICD deactivation is the same.


- "Centered upon patient autonomy and authority over their own medical treatment"
- "Respect for autonomy and individual personhood supports a patient's right to dictate decisions about one's own treatment"



HEART RHYTHM SYMPOSIUM

Kramer DB, et al: Prog Cardiovasc Dis 2012; 55: 290-299

What Does an ICD Shock Feel Like?



ICD Benefits Beyond Shocks to Prevent Sudden Death

- Source of comfort and reassurance for some patients
- Pacing painless and rarely an issue in end-of-life discussions
- Arrhythmia monitoring/management
 - e.g., monitoring AF to guide anticoagulation and other treatment options
- Painless termination of arrhythmias: anti-tachycardia pacing
 - May be palliative in preventing symptomatic VT or slow VT that causes worsening of heart failure



HEART RHYTHM SYMPOSIUM

Article

Annals of Internal Medicine

Brief Communication: Management of Implantable Cardioverter-Defibrillators in Hospice: A Nationwide Survey

Nathan Goldstein, MD; Melissa Carlson, MBA, PhD; Elayne Livote, MPH, MS, MA; and Jean S. Kutner, MD, MSPH


- 414 hospice surveys returned (900 requests)
- 97% admit patients with ICDs
- 58% had patient with shock in last year
- 10% had policy re: deactivation
- 42% had ICDs deactivated




HEART RHYTHM SYMPOSIUM

Ann Intern Med. 2010 March 2; 152(5): 296–299

Physicians' Lack of Comfort Discussing Withdrawal of Specific Life-Sustaining Therapies



Physicians Viewing PM or ICD Withdrawal as Different from Specific Therapy



HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy

This document was developed in collaboration and endorsed by the American College of Cardiology (ACC), the American Geriatrics Society (AGS), the American Academy of Hospice and Palliative Medicine (AAHPM); the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), and the Hospice and Palliative Nurses Association (HPNA).

Rachel Lampert, MD, FHRS,* David L. Hayes, MD, FHRS,[†] George J. Annas, JD, MPH,[‡] Margaret A. Farley, PhD,[¶] Nathan E. Goldstein, MD,[§] Robert M. Hamilton, MD,** G. Neal Kay, MD, FHRS,^{††} Daniel B. Kramer, MD,^{‡‡} Paul S. Mueller, MD, MPH,[†] Luigi Padeletti, MD,^{¶¶} Leo Pozuelo, MD,^{§§} Mark H. Schoenfeld, MD, FHRS,* Panos E. Vardas, MD, PhD,*** Debra L. Wiegand, PhD, RN,^{†††} Richard Zellner, JD, MA^{‡‡‡}

*Yale University, School of Medicine, New Haven, CT, [†]Mayo Clinic, Rochester, MN [‡]Boston University, School of Public Health, Boston, MA, [¶]Yale University Divinity School, New Haven, CT, [§]Mount Sinai School of Medicine New York, NY and the James J Peters VA Medical Center, Bronx, NY, **The Hospital for Sick Children, Toronto, Canada ^{††}The University of Alabama at Birmingham, Birmingham, AL, ^{‡‡}Beth Israel Deaconess Medical Center, Boston, MA, ^{¶¶}University of Florence, Institute of Cardiology, Florence, Italy, ^{§§}Cleveland Clinic, Cleveland, OH, ***Heraklion University Hospital, Crete, Greece, ^{†††}University of Maryland, School of Nursing, Baltimore, MD, ^{‡‡‡}Patient representative; Adjunct lecturer at Case Western Reserve University, Bioethics Department, Cleveland, OH.



HEART RHYTHM SYMPOSIUM

www.hrsonline.org

Case #2 (March 2016) - Outcome

73 yo man with CRT-D, slow VT -> ATP, but no recent shocks

- All tachycardia therapies were disabled.
- CRT pacing left on without any changes
- Referred for hospice
- 2/1/17 Patient's wife called in for med refill. He is bedbound and still on hospice.



HEART RHYTHM SYMPOSIUM

Conclusions

- ICDs prevent sudden cardiac death and improve survival.
- US population aging.
- Patient age and comorbidities impact survival benefit of ICD.
- Detailed discussion regarding benefit and risk for ICD implantation or generator replacement are required, especially as the patient ages and develops other comorbidities.
- Ultimately, the patient has a right to consent or refuse care regarding ICD implantation, replacement, or de-activation.



HEART RHYTHM SYMPOSIUM

Thank You and God Bless Arrhythmia...

